Glanatec

• 

  Glanatec package insert

  Scan the QR code linked to package insert.

  

• At the time of the development of Glanatec® ophthalmic solution 0.4%, glaucoma treatment drugs were prostaglandin (PG) -related drugs, β-blockers, αβ-blockers, α1 blockers, carbonic anhydrase inhibitors, sympathomimetics, and α2 agonist.
  And their compounding agents were commercially available.

  Treatment is basically started with a single agent treatment with a first-line drug, but since it is difficult to control the intraocular pressure below the target value with only one agent, many patients use multiple agents in combination.
  In addition, options may be limited due to restrictions such as side effects, contraindications, and careful administration.

  From the above, a drug having a new mechanism of action has been sought.
  Unlike existing glaucoma treatments, Glanatec® ophthalmic solution 0.4% lowers intraocular pressure by promoting the outflow of aqueous humor from the main outflow tract via the trabecular meshwork-Schlemm's canal based on its “Rho-kinase inhibitory effect ”.